California-based firm 9amHealth, which operates a virtual specialty care platform for cardiometabolic conditions, has secured $26 million in Series B funding led by Define Ventures, alongside participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures.
- Founded in 2021 by Frank Westermann, Anton Kittelberger, Paul Geevarghese, and Bernhard Schandl, 9amHealth is a virtual specialty care company focused on cardiometabolic conditions such as obesity, diabetes, hypertension, and high cholesterol.
- The firm develops an integrated care platform that combines clinical expertise, remote monitoring, at-home lab testing, prescription management, and lifestyle support into a single coordinated system for patients and employers.
- It works by enrolling members into personalized care plans managed by specialists and supported through digital tools, enabling continuous monitoring and treatment without traditional in-person clinic visits.
Details of the deal
- The funding will enable the firm to expand into additional high-cost chronic conditions while scaling its clinical operations, technology platform, and care delivery model to better manage complex patients and reduce employer healthcare and pharmacy costs.
"We're proud to partner with 9amHealth at this pivotal stage. They've demonstrated strong clinical outcomes and cost savings in one of the fastest-growing categories in healthcare. Their platform has the potential to transform how employers manage their most expensive populations," explains Lynne O'Keefe, Founder and Managing Partner at Define Ventures.
